Tendon repair usually requires surgery, which can cost an average of $6,000 in the US and take 12 weeks to fully heal. Image credit: Jo Panuwat D / Shutterstock.

On 19-20 July in Italy, Celularity will present data on the potential therapeutic application of decellularised flowable placental connective tissue matrix (DF-CTM) for tendon repair at the International Conference on Orthopaedics.

The company hypothesised that the lack of blood and cells in tendon tissue slows down its healing process. The DF-CTM would provide the structural and biochemical matrix components to help tendon healing and reduce inflammation.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Tendon repair usually requires surgery, which can cost an average of $6,000 in the US and take 12 weeks to fully heal.

Titled “A Decellularised Flowable Placental Connective Tissue Matrix Supports Cellular Functions of Human Tenocytes In Vitro,” the presentation will summarise the early DF-CTM data.

The in vitro study showed higher tenocyte proliferation and migration in DF-CTM cultures compared to the control.

The DF-CTM cultures showed diminished response to pro-inflammatory markers, including TNF-α, an inflammatory cytokine.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Celularity CEO Robert J Hariri said: “We are very encouraged by the performance of our advanced placental-derived biomaterials, and we believe these data enhance our understanding of the potential application of DF-CTM for tendon repair, which could address a significant unmet need for patients with tendon injuries.

“These early tenocyte data are an important demonstration of our ongoing commitment and focus on innovation leveraging the placental platform we have pioneered.”

According to Celularity’s evaluations, tenocyte proliferation, maintenance of tenocyte phenotype, and attenuated inflammatory response signify a favourable interaction of DF-CTM with human tenocytes.

The US Food and Drug Administration (FDA) in April 2023 approved the first allogeneic stem cell therapy for the treatment of blood cancer.

The company’s immuno-modulatory placenta-derived allogeneic stem cell therapy (IMPACT) candidate, CYNK-101 is being investigated for multiple cancer indications, including lymphoma and gastric carcinomas.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact